Why Psychedelic Stocks Have Crashed in the Last 3 Months

Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the ‘Superior Molecule’

Pre-clinical studies demonstrated multiple advantages, including less patient variability, faster onset of action, shorter duration of effect, and improved brain penetration.
Psychedelic Business Spotlight: November 5

Psychedelic Business Spotlight: November 5

This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
Why We're Excited About Compass Pathways New Clinical Trial Treating PTSD With PsilocybinShutterstock.com

Why We’re Excited About Compass Pathways’ New Clinical Trial Treating PTSD with Psilocybin

,
Compass Pathways (Nasdaq: CMPS) has announced the launch of a brand new psychedelic clinical trial, using psilocybin (the active ingredient in magic mushrooms) to treat PTSD, and there are multiple reasons to be excited about it. The Phase-2…
Shutterstock.com

FDA Approves First Clinical Trial Using Naturally Sourced Psychedelics

This trial, using Filament Health's botanical drug candidates, is the first to assess the direct administration of psilocin.
TRIPP Wants You to 'Be Here Now,' With or Without Ram DassLove Serve Remember Foundation / TRIPP

TRIPP Wants You to ‘Be Here Now,’ With or Without Ram Dass

Psychedelic Spotlight trips with Ram Dass at the 50th anniversary celebration of the spiritual teacher's iconic book.
Could the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser

Can the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser

"Something that people used to speak about only in whispers is now standard policy," says the psychedelics researcher, with 20 years of experience, in a wide-ranging Q&A.

Psychedelic Business Spotlight: October 29

This week in psychedelic business news: MindMed's MDMA research pipeline to treat Autism Spectrum Disorder; Cybin EMBARKs; Awakn and MindCure partner to heal alcoholism.
Psychedelic Business Spotlight: October 22

Psychedelic Business Spotlight: October 22

This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field Trip Health expands its clinical presence in the US; and another psychedelic pharmaceuticals company prepares for the Nasdaq.

Psychedelic Business Spotlight: October 15

This week in psychedelic business news: Cybin inhales; atai Life Sciences expands; DEA grants new psilocybin license; and FDA backs ketamine.
Why Psychedelic Stocks Have Crashed in the Last 3 Months

Why Psychedelic Stocks Have Crashed in the Last 3 Months

Our resident psychedelic investor explains why psychedelic stocks are plummeting, and why patience can pay off big time.